The response to valve injury. A paradigm to understand the pathogenesis of heart valve disease

Cardiovascular Pathology

Volumn 20, Issue 3, 2011, Pages 183-190

  Li, Chen ^a,b   Xu, Songyi ^a,b   Gotlieb, Avrum I ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adherens junctions; Alpha smooth muscle actin; FGF 2; Heart valve disease; TGF b; Valve interstitial cells; Valve repair

Indexed keywords

FIBROBLAST GROWTH FACTOR; MATRIX METALLOPROTEINASE; NOTCH1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANKYLOSING SPONDYLITIS; AORTA STENOSIS; BACTERIAL ENDOCARDITIS; CALCIFICATION; CARCINOID SYNDROME; CELL; CELL ADHESION; CELL INTERACTION; CLINICAL FEATURE; EXPERIMENTAL MODEL; GENE CONTROL; HEALING; HISTOPATHOLOGY; HUMAN; MESENCHYME CELL; MITRAL VALVE STENOSIS; NONHUMAN; NOONAN SYNDROME; OSTEOGENESIS IMPERFECTA; POLYARTERITIS NODOSA; PRIORITY JOURNAL; REVIEW; RHEUMATIC HEART DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; TISSUE REACTION; TREATMENT INDICATION; VALVE INTERSTITIAL CELL; VALVULAR HEART DISEASE; WILLIAMS BEUREN SYNDROME;

ANIMALS; AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; CELL COMMUNICATION; HUMANS; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 79955681646     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carpath.2010.09.008     Document Type: Review

References (70)

1. Araki T, Chan G, Newbigging S, Morikawa L, Bronson RT, Neel BG. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci U S A 2009;106:4736-41.
2. Yang JH, Wylie-Sears J, Bischoff J. Opposing actions of Notch1 and VEGF in post-natal cardiac valve endothelial cells. Biochem Biophys Res Commun 2008;374:512-6.
3. Bonita RE, Cohen IS, Berko BA. Valvular heart disease in osteogenesis imperfecta: presentation of a case and review of the literature. Echocardiography 2010;27:69-73.
4. Pober BR, Johnson M, Urban Z. Mechanisms and treatment of cardiovascular disease in Williams-Beuren syndrome. J Clin Invest 2008;118:1606-15. (Pubitemid 351632362)
5. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001;104:2525-32. (Pubitemid 33104788)
6. Cripe L, Andelfinger G, Martin LJ, Shooner K, Benson DW. Bicuspid aortic valve is heritable. J Am Coll Cardiol 2004;44:138-43. (Pubitemid 38968472)
7. Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 2007;171:1407-18. (Pubitemid 350158303)
8. Durbin AD, Gotlieb AI. Advances towards understanding heart valve response to injury. Cardiovasc Pathol 2002;11:69-77. (Pubitemid 34273661)
9. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4. (Pubitemid 27116107)
10. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997;95:2262-70.
11. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142-7. (Pubitemid 29325741)
12. Napoli C, Cacciatore F. Novel pathogenic insights in the primary prevention of cardiovascular disease. Prog Cardiovasc Dis 2009;51:503-23.
13. O'Brien KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscl Throm Vas 2006;26:1721-8. (Pubitemid 44305324)
14. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993;21:1220-5. (Pubitemid 23106200)
15. Xu S, Liu AC, Gotlieb AI. Common pathogenic features of atherosclerosis and calcific aortic stenosis: role of transforming growth factor-beta. Cardiovasc Pathol 2009;19(4):236-47.
16. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Goncalves F, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-61. (Pubitemid 46177435)
17. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56.
18. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97. (Pubitemid 40958435)
19. Chan KL, Teo K, Tam J, Dumesnil JG. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J 2007;153:925-31. (Pubitemid 46823966)
20. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002;105:2660-5. (Pubitemid 34596044)
21. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005;112:I229-234.
22. Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005;91:806-10. (Pubitemid 40769233)
23. Anger T, Carson W, Weyand M, Daniel WG, Hoeher M, Garlichs CD. Atherosclerotic inflammation triggers osteogenic bone transformation in calcified and stenotic human aortic valves: still a matter of debate. Exp Mol Pathol 2009;86:10-7.
24. Yoshioka M, Yuasa S, Matsumura K, Kimura K, Shiomi T, Kimura N, et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med 2006;12:1151-9. (Pubitemid 44527350)
25. Hakuno D, Kimura N, Yoshioka M, Fukuda K. Molecular mechanisms underlying the onset of degenerative aortic valve disease. J Mol Med 2009;87:17-24.
26. Soini Y, Salo T, Satta J. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum Pathol 2003;34:756-63. (Pubitemid 37040610)
27. Chalajour F, Treede H, Ebrahimnejad A, Lauke H, Reichenspurner H, Ergun S. Angiogenic activation of valvular endothelial cells in aortic valve stenosis. Exp Cell Res 2004;298:455-64. (Pubitemid 38950862)
28. Messier RH, Bass BL, Aly HM, Jones JL, Domkowski PW, Wallace RB, et al. Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. J Surg Res 1994;57:1-21. (Pubitemid 24243231)
29. Yacoub MH, Kilner PJ, Birks EJ, Misfeld M. The aortic outflow and root: a tale of dynamism and crosstalk. Ann Thorac Surg 1999;68:S37-S43. (Pubitemid 29521177)
30. Schoen FJ. Aortic valve structure-function correlations: role of elastic fibers no longer a stretch of the imagination. J Heart Valve Dis 1997;6:1-6.
31. Filip DA, Radu A, Simionescu M. Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells. Circ Res 1986;59:310-20. (Pubitemid 17178125)
32. Mulholland DL, Gotlieb AI. Cell biology of valvular interstitial cells. Can J Cardiol 1996;12:231-6. (Pubitemid 26097855)
33. Aikawa E, Whittaker P, Farber M, Mendelson K, Padera RF, Aikawa M, et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult - Implications for postnatal adaptation, pathology, and tissue engineering. Circulation 2006;113:1344-52. (Pubitemid 43739456)
34. Weston MW, Yoganathan AP. Biosynthetic activity in heart valve leaflets in response to in vitro flow environments. Ann Biomed Eng 2001;29:752-63. (Pubitemid 33013698)
35. Rabkin-Aikawa E, Farber M, Aikawa M, Schoen FJ. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J Heart Valve Dis 2004;13:841-7.
36. Choi JH, Do Y, Cheong C, Koh H, Boscardin SB, Oh YS, et al. Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. J Exp Med 2009;206:497-505.
37. Liu AC, Gotlieb AI. Characterization of cell motility in single heart valve interstitial cells in vitro. Histol Histopathol 2007;22:873-82. (Pubitemid 47034153)
38. Lester W, Rosenthal A, Granton B, Gotlieb AI. Porcine mitral valve interstitial cells in culture. Lab Invest 1988;59:710-9. (Pubitemid 19009733)
39. Gotlieb AI, Spector W. Migration into an in vitro experimental wound: a comparison of porcine aortic endothelial and smooth muscle cells and the effect of culture irradiation. Am J Pathol 1981;103:271-82. (Pubitemid 11112981)
40. Anderson S, DiCesare L, Tan I, Leung T, SundarRaj N. Rho-mediated assembly of stress fibers is differentially regulated in corneal fibroblasts and myofibroblasts. Exp Cell Res 2004;298:574-83. (Pubitemid 38950872)
41. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992;70:401-10.
42. Durbin A, Nadir NA, Rosenthal A, Gotlieb AI. Nitric oxide promotes in vitro interstitial cell heart valve repair. Cardiovasc Pathol 2005;14:12-8. (Pubitemid 40248427)
43. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835-70. (Pubitemid 36828927)
44. Ortega S, Ittmann M, Tsang SH, Ehrlich M, Basilico C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci U S A 1998;95:5672-7. (Pubitemid 28224154)
45. Gotlieb AI, Rosenthal A, Kazemian P. Fibroblast growth factor 2 regulation of mitral valve interstitial cell repair in vitro. J Thorac Cardiov Sur 2002;124:591-7.
46. Liu AC, Gotlieb AI. Transforming growth factor-beta regulates in vitro heart valve repair by activated valve interstitial cells. Am J Pathol 2008;173:1275-85.
47. Connolly JM, Bakay MA, Fulmer JT, Gorman RC, Gorman JH, Oyama MA, et al. Fenfluramine disrupts the mitral valve interstitial cell response to serotonin. Am J Pathol 2009;175:988-97.
48. Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-beta: biological function and chemical structure. Science 1986;233:532-4. (Pubitemid 16019904)
49. Chin D, Boyle GM, Parsons PG, Coman WB. What is transforming growth factor-beta (TGF-beta)? Br J Plast Surg 2004;57:215-21. (Pubitemid 38380437)
50. Cho HJ, Baek KE, Saika S, Jeong MJ, Yoo J. Snail is required for transforming growth factor-beta-induced epithelial-mesenchymal transition by activating PI3 kinase/Akt signal pathway. Biochem Biophys Res Commun 2007;353:337-43. (Pubitemid 46014570)
51. Choy M, Armstrong MT, Armstrong PB. Regulation of proliferation of embryonic heart mesenchyme: role of transforming growth factor-beta 1 and the interstitial matrix. Dev Biol 1990;141:421-5.
52. Cogan JG, Subramanian SV, Polikandriotis JA, Kelm RJ, Strauch AR. Vascular smooth muscle alpha-actin gene transcription during myofibroblast differentiation requires Sp1/3 protein binding proximal to the MCAT enhancer. J Biol Chem 2002;277:36433-42.
53. Conery AR, Cao Y, Thompson EA, Townsend CM, Ko TC, Luo K. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol 2004;6:366-72. (Pubitemid 38584827)
54. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004;29:265-73.
55. Taylor IW, Wrana JL. SnapShot: The TGFbeta pathway interactome. Cell 2008;133:378.e1.
56. Lester WM, Gotlieb AI. In vitro repair of the wounded porcine mitral valve. Circ Res 1988;62:833-45.
57. Walker GA, Masters KS, Shah DN, Anseth KS, Leinwand LA. Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 2004;95:253-60. (Pubitemid 39056285)
58. Masszi A, Fan L, Rosivall L, McCulloch CA, Rotstein OD, Mucsi I, et al. Integrity of cell-cell contacts is a critical regulator of TGF-beta 1- induced epithelial-to-myofibroblast transition: role for beta-catenin. Am J Pathol 2004;165:1955-67. (Pubitemid 39578374)
59. Barth M, Schumacher H, Kuhn C, Akhyari P, Lichtenberg A, Franke WW. Cordial connections: molecular ensembles and structures of adhering junctions connecting interstitial cells of cardiac valves in situ and in cell culture. Cell Tissue Res 2009;337:63-77.
60. Nelson WJ. Regulation of cell-cell adhesion by the cadherin-catenin complex. Biochem Soc Trans 2008;36:149-55. (Pubitemid 351570584)
61. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Bi 2004;20:781-810. (Pubitemid 39488658)
62. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80.
63. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
64. Hurlstone AF, Haramis AP, Wienholds E, Begthel H, Korving J, Van Eeden F, et al. The Wnt/beta-catenin pathway regulates cardiac valve formation. Nature 2003;425:633-7. (Pubitemid 37280148)
65. Liebner S, Cattelino A, Gallini R, Rudini N, Iurlaro M, Piccolo S, et al. Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol 2004;166:359-67. (Pubitemid 39031239)
66. Alfieri CM, Cheek J, Chakraborty S, Yutzey KE. Wnt signaling in heart valve development and osteogenic gene induction. Dev Biol 2009;338:127-35.
67. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009;20:765-76.
68. Morrisey EE. Wnt signaling and pulmonary fibrosis. Am J Pathol 2003;162:1393-7. (Pubitemid 36512820)
69. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006;47:1707-12.
70. Wirrig EE, Yutzey KE. Transcriptional regulation of heart valve development and disease. Cardiovasc Pathol 2010 (in press).